Related Experiment Video
Updated: Mar 11, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
A Comparison Between NOACs and Warfarin on Time to Elective Cardioversion
Siva Krothapalli1, Prashant D Bhave1
1University of Iowa Hospitals and Clinics; Iowa City, IA.
Journal of Atrial Fibrillation
|December 3, 2016
Summary
Warfarin and novel oral anticoagulants reduce thromboembolism risk during atrial fibrillation cardioversion. Novel agents offer consistent anticoagulation without frequent monitoring, improving procedural safety.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardioversion for atrial fibrillation carries a risk of thromboembolism, mitigated by oral anticoagulation.
- Warfarin, a traditional oral anticoagulant, requires careful dosing and monitoring (INR) for therapeutic efficacy.
- Novel oral anticoagulants (NOACs) offer consistent anticoagulation without routine monitoring.
Approach:
- This review examines existing literature comparing Warfarin and NOACs.
- The focus is on their efficacy and safety in the context of elective cardioversion.
- Key outcomes include thromboembolic event rates and anticoagulation consistency.
Key Points:
- Consistent anticoagulation is crucial for safe cardioversion.
- Warfarin's therapeutic window can be challenging to maintain.
- NOACs provide predictable anticoagulation, potentially simplifying peri-cardioversion management.
Conclusions:
- Novel oral anticoagulants may offer a safer and more convenient alternative to Warfarin for cardioversion.
- Further research can solidify the role of NOACs in optimizing cardioversion protocols.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:29Venous Thrombosis III: Interprofessional Care
433
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
433
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K